Adalimumab - MedImmune/AbbVie

Drug Profile

Adalimumab - MedImmune/AbbVie

Alternative Names: ABT-D2E7; D2E7; Humira; LU 200134; Raheara

Latest Information Update: 01 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cambridge Antibody Technology
  • Developer AbbVie; Eisai Co Ltd; Interstitial Cystitis Study
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics; Skin disorder therapies
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveitis; Hidradenitis suppurativa
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Behcet's syndrome; Crohn's disease; Hidradenitis suppurativa; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis; Ulcerative colitis; Uveitis
  • Phase III Pustular psoriasis; Pyoderma
  • Discontinued Interstitial cystitis

Most Recent Events

  • 03 Nov 2017 AbbVie completes a long-term extension study for Crohn's disease in USA, Canada, Austria, Belgium, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, the Netherlands, Poland, Puerto Rico, Romania, Slovakia, Spain, Switzerland, Ukraine and United Kingdom (SC) (NCT02185014)
  • 17 Oct 2017 Abbott terminates a phase III trial in Rheumatoid arthritis (Combination therapy) in Germany (NCT02150473)
  • 17 Oct 2017 Phase-III clinical trials in Pyoderma in Japan (SC) (NCT03311464)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top